2024-10-11 18:52:00
Sanofi announced on Friday that it was negotiating with the investment fund CD&R to give up control of its subsidiary Opella, responsible in particular for the production of Doliprane.
MPs from all sides urged the government this Friday, October 11, to block, in the name of French health sovereignty, the sale of Opella, a subsidiary of Sanofi responsible in particular for the production of Doliprane. Doliprane, the best-selling drug in France, is about to move under the American flag, after Sanofi announced on Friday that it is in talks with the CD&R investment fund to give up control of its subsidiary.
An operation that “represents a very concerning issue for our national security,” write about sixty deputies from the Ensemble pour la République (ex-Renaissance), Horizons, Démocrate (ex-MoDem) and Republican Right (ex-LR) groups, on the initiative of MP Charles Rodwell (EPR), who Le Figaro-TV receives on the show “Points de Vue” this Monday at 12:00. “Doliprane is an essential medicine for the health of millions of French people”AND “success for the Sanofi group”and the operation would go against the “restoration of French sovereignty in health matters”they warn in a joint letter to Economy Minister Antoine Armand.
Wauquiez steps up to the plate
The head of the right-wing republican group, Laurent Wauquiez, and the general rapporteur of the Social Security budget, Yannick Neuder (DR), also wrote to the minister with the same request: “It is essential that the State acts to protect our industrial flagships and guarantee France’s health sovereignty”. Second The Echoes The potential American buyer has offered more than 15 billion euros to get its hands on Opella, which claims to be the world’s number three in non-prescription medicines, vitamins, minerals and nutritional supplements.
This subsidiary oversees around a hundred brands including the popular Doliprane but also Mucosolvan, Maalox and Novanuit. The Ministers of Economy, Antoine Armand, and Industry, Marc Ferracci, asked on Friday for the commitment of Sanofi and the future buyer to guarantee the “maintain offices and decision-making centers on the national territory” et “Opella’s French industrial footprint”.
#MPs #request #block #sale #Sanofi #subsidiary
